Fetal carbamazepine syndrome
Fetal carbamazepine syndrome is a drug-related embryofetopathy that can occur when an embryo/fetus is exposed to carbamazepine and that is characterized by facial dysmorphism with some similarities to that seen in fetal valproate syndrome (see this term) such as epicanthal folds upward slanting palpebral fissures short nose micrognathia and malar hypoplasia as well as nail dysplasia and major anomalies including cleft lip/palate neural tube defects and cardiac anomalies. In utero exposure to carbamazepine in combination with valproate has been associated with significant developmental delay (particularly affecting verbal intelligence) and a high rate of congenital anomalies.
Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview.
Reference: Access aggregated data from Orphanet at Orphadata.
Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version April 2024
Newly diagnosed with
Fetal carbamazepine syndrome?
Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.
Clinical Trials
For a list of clinical trials in this disease area, please click here.